Publications by authors named "Doug Galasko"

Claim this Profile
K
Kidney function is associated with plasma ATN biomarkers among Hispanics/Latinos: SOL-INCA and HCHS/SOL results.
Natasha Z Anita, Wassim Tarraf, Sayaka Kuwayama, Freddie Márquez, Charles DeCarli, Doug Galasko

Alzheimers Res Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A preliminary study on plasma markers across cognitive stages and links to a history of mild traumatic brain injury.
Christian LoBue, Barbara E Stopschinski, Nil Saez Calveras, Amber Salter, Doug Galasko

J Alzheimers Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Validation of the English Version of the Dépistage Cognitif de Québec: a Cognitive Screening Tool for Atypical Dementias.
Synthia Meilleur-Durand, Marianne Lévesque, Frederic St-Onge, Mario Masellis, Ging-Yuek Robin Hsiung, Doug Galasko

Arch Clin Neuropsychol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concerns with the new biological research criteria for synucleinopathy.
Jennifer G Goldman, Bradley F Boeve, Doug Galasko, James E Galvin, James B Leverenz

Lancet Neurol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study.
Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Cornelis Blauwendraat, Doug Galasko

Mov Disord Clin Pract· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer's disease.
Joseph R Herdy, Larissa Traxler, Ravi K Agarwal, Lukas Karbacher, Johannes C M Schlachetzki, Doug Galasko

Cell Stem Cell· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
α-Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α-Synuclein in the Context of Co-Pathology and Non-LBD Diagnoses.
Moriah R Arnold, David G Coughlin, Barbara H Brumbach, Denis S Smirnov, Luis Concha-Marambio, Doug R Galasko

Ann Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
Allan I Levey, Deqiang Qiu, Liping Zhao, William T Hu, Duc M Duong, Doug Galasko

Brain· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting.
Jennifer G Goldman, Bradley F Boeve, Melissa J Armstrong, Doug R Galasko, James E Galvin

Alzheimers Res Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.
Jennifer G Goldman, Leah K Forsberg, Bradley F Boeve, Melissa J Armstrong, David J Irwin, Doug Galasko

Alzheimers Res Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Tanya Simuni, Michael C Brumm, Liz Uribe, Chelsea Caspell-Garcia, Christopher S Coffey, Doug Galasko

Mov Disord· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Tanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Christopher S Coffey, Doug Galasko

Lancet Neurol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.
Kenneth Marek, Sohini Chowdhury, Andrew Siderowf, Shirley Lasch, Christopher S Coffey, Doug Galasko

Ann Clin Transl Neurol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
Tanya Simuni, Andrew Siderowf, Shirley Lasch, Chris S Coffey, Chelsea Caspell-Garcia, Doug Galasko

Mov Disord· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOE ε4 increases risk for dementia in pure synucleinopathies.
Debby Tsuang, James B Leverenz, Oscar L Lopez, Ronald L Hamilton, David A Bennett, Doug Galasko

JAMA Neurol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.
Debby Tsuang, James B Leverenz, Oscar L Lopez, Ronald L Hamilton, David A Bennett, Doug Galasko

Neurology· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease.
Lynn M Bekris, Steve Millard, Franziska Lutz, Gail Li, Doug R Galasko

Am J Med Genet B Neuropsychiatr Genet· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Welcome to Alzheimer's research & therapy.
Ann Donnelly, Doug Galasko, Todd Golde, Frances Mulvany, Gordon Wilcock

Alzheimers Res Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.
Raj N Kalaria, Gladys E Maestre, Raul Arizaga, Robert P Friedland, Doug Galasko

Lancet Neurol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.
Zaven S Khachaturian, Ronald C Petersen, Serge Gauthier, Neil Buckholtz, Jodey P Corey-Bloom, Doug Galasko

Alzheimers Dement· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of LRP in TGFbeta2-mediated neuronal uptake of Abeta and effects on memory.
Marni E Harris-White, Zerlinde Balverde, Giselle P Lim, Peter Kim, Sheryl A Miller, Doug Galasko

J Neurosci Res· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis